Skip to main content
SpringerLink
Log in

A Review of Polymorphisms in the Human Gene for Inducible Nitric Oxide Synthase (NOS2) in Patients with Malaria

  • Published:
Sepsis

Abstract

Significant variability exists in host responses to malaria in different human populations. These epidemiological data have prompted a search for genetic variations that determine host responses to malaria. This review focuses on polymorphisms in the promoter region of inducible nitric oxide synthase (NOS2) as a source of genetic differences in the response of patients to infection with malaria. Nitric oxide (NO), a lipid soluble free radical, mediates host resistance to infectious organisms including parasites. NO is produced by three different NO synthases (NOS) in humans. Research on NO and malaria has focused on the cytokine inducible isoform of NOS (NOS2). The role of NO in host responses to infection and inflammation is likely to be both detrimental and beneficial to the host; this is reflected by the effects of NO on different host tissues and on parasite viability. Therefore, studies of the regulation of NOS2 transcription by different human cell types are important to gain a better understanding of the effects of malaria infection on different host tissues. Several important transcription factor binding sites in the NOS2 promoter region have been identified and represent potential sites of genetic heterogeneity in NOS2 transcription during malaria infection. Furthermore, a variety of studies have been performed to determine the role of NO in the pathogenesis of malaria in humans. Taken together, these studies suggest that high systemic NO production is associated with milder disease and increased parasite clearance while impaired systemic NO production (but increased central nervous system NOS2 expression) is associated with cerebral malaria. There are several possible mechanisms that might explain differences in NO production in malaria patients including functional polymorphisms in the promoter region of NOS2. To date, two NOS2 promoter polymorphisms, G-954C and a CCTTT microsatellite repeat, have been identified, and are associated with disease severity in populations of African patients with malaria. The relationship of these polymorphisms to malaria disease severity in other populations remains controversial and is the subject of ongoing studies. Likewise, the functional significance (relative to NO production) of these polymorphisms in unknown. Therefore, future studies will be necessary to determine whether other polymorphisms in the NOS2 gene are associated with malaria disease severity and to determine the functional effects of these polymorphisms on malaria disease severity and NOS2 transcription.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. Severe and complicated malaria. Trans Royal Soc Tropical Med and Hygiene 1990; 84:1–65.

    Google Scholar 

  2. Hill AV. The immunogenetics of human infectious diseases. Ann Rev Immunol 1998;16:593–617.

    Google Scholar 

  3. Kun JF, Mordmuller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 1998; 351:265–266.

    Google Scholar 

  4. Burgner D, Xu WM, Rockett K, et al. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet 1998;352:1193–1194.

    Google Scholar 

  5. Levesque MC, Hobbs MR, Anstey NM, et al. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production and disease severity in Tanzania children with malaria. J Infect Dis 1999;180:1994–2002.

    Google Scholar 

  6. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997;99:2818–2825.

    Google Scholar 

  7. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997; 100:2417–2423.

    Google Scholar 

  8. Clark IA, Rockett KA. Nitric oxide and parasitic disease. Advances Parasitol 1996;37:1–56.

    Google Scholar 

  9. Anstey NM, Weinberg JB, Granger DL. Nitric oxide in malaria. In: Fang F, ed. Nitric Oxide and Infection. New York: Plenum Publishing Corporation, 1999:311–341.

    Google Scholar 

  10. Clark IA, Rockett KA, Cowden WB. Proposed link between cytokines, nitric oxide, and human cerebral malaria. Parasitol Today 1991; 7:205–207.

    Google Scholar 

  11. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002–2012.

    Google Scholar 

  12. Clancy RM, Abramson SB. Nitric oxide: A novel mediator of inflammation. Proc Soc Exper Biol and Med 1995;210: 93–101.

    Google Scholar 

  13. Weinberg JB. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: A review. Mol Med 1998; 4:557–591.

    Google Scholar 

  14. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Ann Rev Biochem 1994; 63:175–195.

    Google Scholar 

  15. Wray G, Thiemermann C. Nitric oxide in sepsis. In: Fang FC, ed. Nitric Oxide and Infection. New York: Kluwer Academic/ Plenum Publishers, 1999:265–280.

    Google Scholar 

  16. Privalle C, Talarico T, Keng T, DeAngelo J. Pyridoxalated hemoglobin polyoxyethylene: a nitric oxide scavenger with antioxidant activity for the treatment of nitric oxideinduced shock. Free Radical Biol & Med 2000; 28:1507–1517.

    Google Scholar 

  17. Weinberg JB, Granger DL, Pisetsky DS, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exper Med 1994;179:651–661.

    Google Scholar 

  18. Ushmorov A, Ratter F, Lehmann V, Droge W, Schirrmacher V, Umansky V. Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release. Blood 1999;93:2342–2352.

    Google Scholar 

  19. Bonner FT, Stedman G. The chemistry of nitric oxide and redox-related species. In: Feelisch M, Stamler JS, eds. Methods in Nitric Oxide Research. Chichester: John Wiley & Sons, 1996:3–18.

    Google Scholar 

  20. Seguin MC, Klotz FW, Schneider I, et al. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exper Med 1994;180:353–358.

    Google Scholar 

  21. Rockett KA, Awburn MM, Cowden WB, Clark IA. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect & Immun 1991;59:3280–3283.

    Google Scholar 

  22. Taylor-Robinson AW. Antimalarial activity of nitric oxide: cytostasis and cytotoxicity towards Plasmodium falciparum. Biochem Soc Trans 1997;25:262S.

    Google Scholar 

  23. Taylor BS, Alarcon LH, Billiar TR. Inducible nitric oxide synthase in the liver: regulation and function. Biochemistry (Moscow) 1998;63:766–781.

    Google Scholar 

  24. Genaro AM, Hortelano S, Alvarez A, Martinez C, Bosca L. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. J Clin Invest 1995;95:1884–1890.

    Google Scholar 

  25. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exper Med 1997;185: 601–607.

    Google Scholar 

  26. Li J, Billiar TR, Talanian RV, Kim YM. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem & Biophys Res Commun 1997;240: 419–424.

    Google Scholar 

  27. Mohr S, Zech B, Lapetina EG, Brune B. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem & Biophys Res Commun 1997;238:387–391.

    Google Scholar 

  28. Mannick JB, Hausladen A, Liu L, et al. Fas-induced caspase denitrosylation. Science 1999;284:651–654.

    Google Scholar 

  29. Paul-Clark MJ, Gilroy DW, Willis D, Willoughby DA, Tomlinson A. Nitric oxide synthase inhibitors have opposite effects on acute inflammation depending on their route of administration. J Immunol 2001;166:1169–1177.

    Google Scholar 

  30. McCartney-Francis NL, Song XY, Mizel DE, Wahl SM. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease. J Immunol 2001;166:2734–2740.

    Google Scholar 

  31. Chartrain NA, Geller DA, Koty PP, et al. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J Biol Chem 1994;269: 6765–2772.

    Google Scholar 

  32. de Vera ME, Shapiro RA, Nussler AK, et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci USA 1996;93:1054–1059.

    Google Scholar 

  33. Linn SC, Morelli PJ, Edry I, Cottongim SE, Szabo C, Salzman AL. Transcriptional regulation of human inducible nitric oxide synthase gene in an intestinal epithelial cell line. Am J Physiol 1997;272:G1499–G1508

    Google Scholar 

  34. Laubach VE, Zhang CX, Russell SW, Murphy WJ, Sherman PA. Analysis of expression and promoter function of the human inducible nitric oxide synthase gene in DLD-1 cells and monkey hepatocytes. Biochim Biophys Acta 1997;1351: 287–295.

    Google Scholar 

  35. Taylor BS, de Vera ME, Ganster RW, et al. Multiple NFkappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998;273:15148–15156.

    Google Scholar 

  36. Marks-Konczalik J, Chu SC, Moss J. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. J Biol Chem 1998;273: 22201–22208.

    Google Scholar 

  37. Kleinert H, Wallerath T, Fritz G, et al. Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAKSTAT, AP-1 and NF-kappaB-signaling pathways. Br J Pharmacol 1998;125:193–201.

    Google Scholar 

  38. Ganster RW, Geller DA. Molecular regulation of inducible nitric oxide synthase. In: Ignarro LJ, ed. Nitric Oxide Biology and Pathobiology. San Diego: Academic Press, 2000: 129–156.

    Google Scholar 

  39. Eissa NT, Strauss AJ, Haggerty CM, Choo EK, Chu SC, Moss J. Alternative splicing of human inducible nitric-oxide synthase mRNA. tissue-specific regulation and induction by cytokines. J Biol Chem 1996;271:27184–27187.

    Google Scholar 

  40. Rodriguez-Pascual F, Hausding M, Ihrig-Biedert I, et al. Complex contribution of the 3'-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR. J Biol Chem 2000;275:26040–26049.

    Google Scholar 

  41. Mellott JK, Nick HS, Waters MF, Billiar TR, Geller DA, Chesrown SE. Cytokine-induced changes in chromatin structure and in vivo footprints in the inducible NOS promoter. Am J Physiol LungCell & Mol Physiol 2001;280: L390–L399.

    Google Scholar 

  42. Weinberg JB, Misukonis MA, Shami PJ, et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995;86:1184–1195.

    Google Scholar 

  43. Sharara AI, Perkins DJ, Misukonis MA, Chan SU, Dominitz JA, Weinberg JB. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNAand protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. J Exp Med 1997;186: 1495–1502.

    Google Scholar 

  44. Perkins DJ, St. Clair EW, Misukonis MA, Weinberg JB. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthrit & Rheum 1998;41:2205–2210.

    Google Scholar 

  45. Geller DA, de Vera ME, Russell DA, et al. A central role for IL-1 beta in the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase. IL-1 beta induces hepatic nitric oxide synthesis. J Immunol 1995;155:4890–4898.

    Google Scholar 

  46. MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem & Biophys Res Commun 1993;196: 1330–1334.

    Google Scholar 

  47. Rosenkranz-Weiss P, Sessa WC, Milstein S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest 1994;93:2236–2243.

    Google Scholar 

  48. Orpana A, Ranta V, Mikkola T, Viinikka L, Ylikorkala O. Inducible nitric oxide and prostacyclin productions are differently controlled by extracellular matrix and cell density in human vascular endothelial cells. J Cell Biochem 1997;64:538–546.

    Google Scholar 

  49. Tachado SD, Gerold P, McConville MJ, et al. Glycosylphosphatidylinositol toxin of Plasmodium induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase-dependent and protein kinase C-dependent signaling pathway. J Immunol 1996;156:1897–1907.

    Google Scholar 

  50. Nunokawa Y, Oikawa S, Tanaka S. Human inducible nitric oxide synthase gene is transcriptionally regulated by nuclear factor-kappaB dependent mechanism. Biochem & Biophys Res Commun 1996;223:347–352.

    Google Scholar 

  51. Kolyada AY, Savikovsky N, Madias NE. Transcriptional regulation of the human iNOS gene in vascular-smooth-muscle cells and macrophages: evidence for tissue specificity. Biochem Biophys Res Commun 1996;220:600–605.

    Google Scholar 

  52. Sakitani K, Nishizawa M, Inoue K, Masu Y, Okumura T, Ito S. Synergistic regulation of inducible nitric oxide synthase gene by CCAAT/enhancer-binding protein beta and nuclear factor-kappaB in hepatocytes. Genes to Cells 1998;3:321–330.

    Google Scholar 

  53. Spitsin SV, Farber JL, Bertovich M, Moehren G, Koprowski H, Michaels FH. Human-and mouse-inducible nitric oxide synthase promoters require activation of phosphatidylcholine-specific phospholipase C and NF-kappa B. Mol Med 1997;3:315–326.

    Google Scholar 

  54. Chu SC, Marks-Konczalik J, Wu HP, Banks TC, Moss J. Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. Biochem & Biophys Res Commun 1998;248:871–878.

    Google Scholar 

  55. Cot S, Ringwald P, Mulder B, et al. Nitric oxide in cerebral malaria [letter]. J Infect Dis 1994;169:1417–1418.

    Google Scholar 

  56. Nussler AK, Eling W, Kremsher PG. Patients with Plasmodium falciparum malaria and Plasmodium vivax malaria show increased nitrite and nitrate plasma levels [letter]. J Infect Dis 1994;169:1418–1419.

    Google Scholar 

  57. Prada J Kremsner PG. Enhanced production of reactive nitrogen intermediates in human and murine malaria. Parasitol Today 1995;11:409–410.

    Google Scholar 

  58. al-Yaman FM, Mokela D, Genton B, Rockett KA, Alpers MP, Clark IA. Association between serum levels of reactive nitrogen intermediates and coma in children with cerebral malaria in Papua New Guinea. Trans Royal Soc Trop Med & Hygiene 1996;90:270–273.

    Google Scholar 

  59. al-Yaman F, Awburn MM, Clark IA. Serum creatinine levels and reactive nitrogen intermediates in children with cerebral malaria in Papua New Guinea. Trans Royal Soc Trop Med & Hygiene 1997;91:303–305.

    Google Scholar 

  60. Kremsner PG, Winkler S, Wildling E, et al. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitological and clinical cure in Plasmodium falciparum malaria. Trans Royal Soc Trop Med & Hygiene 1996;90:44–47.

    Google Scholar 

  61. Weiss G, Thuma PE, Mabeza G, Werner ER, Herold M, Gordeuk VR. Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. J Infect Dis 1997;175:226–230.

    Google Scholar 

  62. al-Yaman FM, Genton B, Clark IA. The ratio of reactive nitrogen intermediates to tumour necrosis factor and clinical outcome of falciparum malaria disease. Trans Royal Soc Trop Med & Hygiene 1998;92:417–420.

    Google Scholar 

  63. Taylor AM, Day NP, Sinh DX, et al. Reactive nitrogen intermediates and outcome in severe adult malaria. Trans Royal Soc Trop Med & Hygiene 1998;92:170–175.

    Google Scholar 

  64. Torre D, Ferrario G, Matteelli A, et al. Levels of circulating nitrate/nitrite and gamma interferon not increased in uncomplicated malaria. Infection 1998;26:301–303.

    Google Scholar 

  65. Arun Kumar C, Das UN. Lipid peroxides, nitric oxide and essential fatty acids in patients with Plasmodium falciparum malaria. Prostaglandins Leukotrienes & Essential Fatty Acids 1999;61:255–258.

    Google Scholar 

  66. Anstey NM, Weinberg JB, Hassanali MY, et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exper Med 1996;184: 557–567.

    Google Scholar 

  67. Chiwakata CB, Hemmer CJ, Dietrich M. High levels of inducible nitric oxide synthase mRNA are associated with increased monocyte counts in blood and have a beneficial role in Plasmodium falciparum malaria. Infect & Immun 2000;68:394–399.

    Google Scholar 

  68. Perkins DJ, Kremsner PG, Schmid D, Misukonis MA, Kelly MA, Weinberg JB. Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy gabonese children with prior mild or severe malaria. Infect & Immun 1999;67:4977–4981.

    Google Scholar 

  69. Kun JF, Mordmuller B, Perkins DJ, et al. Nitric oxide synthase2Lambarene mutation, increased nitric oxide production and protection against malaria. J Infect Dis 2001;330–336.

  70. Agbenyega T, Angus B, Bedu-Addo G, et al. Plasma nitrogen oxides and blood lactate concentrations in Ghanaian children with malaria. Trans Royal Soc Trop Med&Hygiene 1997;91:298–302.

    Google Scholar 

  71. Dondorp AM, Planche T, de Bel EE, et al. Nitric oxides in plasma, urine, and cerebrospinal fluid in patients with severe falciparum malaria. AmJ Trop Med & Hygiene 1998;59: 497–502.

    Google Scholar 

  72. Weiss G, Thuma PE, Biemba G, Mabeza G, Werner ER, Gordeuk VR. Cerebrospinal fluid levels of biopterin, nitric oxide metabolites, and immune activation markers and the clinical course of human cerebral malaria. J Infect Dis 1998;177:1064–1068.

    Google Scholar 

  73. Maneerat Y, Viriyavejakul P, Punpoowong B, et al. Inducible nitric oxide synthase expression is increased in the brain in fatal cerebral malaria. Histopathology 2000;37:269–277.

    Google Scholar 

  74. Clark I, Whitten R, Molyneux M, Taylor L. Salicylates, nitric oxide, malaria, and Reye's syndrome. Lancet 2001; 57:625–627.

    Google Scholar 

  75. Grau GE, Taylor TE, Molyneux ME, et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989;320:1586–1591.

    Google Scholar 

  76. Kwiatkowski D, Hill AV, Sambou I, et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990;336:1201–1204.

    Google Scholar 

  77. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D. Variation in the tnf-alpha promoter region associated with susceptibility to cerebral malaria. Nature1994;371:508–511.

    Google Scholar 

  78. Granger DL, Miller WC, Hibbs JB. Methods of analyzing nitric oxide production in the immune response. In: Feelisch M, Stamler JS, eds. Methods in Nitric Oxide Research. Chichester: John Wiley & Sons, 1996:603–618.

    Google Scholar 

  79. Anstey NM, Granger DL, Hassanali MY, Mwaikambo ED, Duffy PE, Weinberg JB. Nitric oxide, malaria, and anemia: inverse relationship between nitric oxide production and hemoglobin concentration in asymptomatic, malaria-exposed children. Am J Trop Med & Hygiene 1999;61:249–252.

    Google Scholar 

  80. Annane D, Sanquer S, Sebille V, et al. Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet 2000;355:1143–1148.

    Google Scholar 

  81. Clark IA, al Yaman FM, Jacobson LS. The biological basis of malarial disease. Internatl J Parasitol 1997;27:1237–1249.

    Google Scholar 

  82. Luty AJ, Perkins DJ, Lell B, et al. Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect & Immun 2000;68:3909–3915.

    Google Scholar 

  83. Gazzinelli RT, Oswald IP, James SL, Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFNgamma-activated macrophages. J Immunol 1992;148: 792–1796.

    Google Scholar 

  84. Perkins DJ, Weinberg JB, Kremsner PG. Reduced interleukin-12 and transforming growth factor-b1 in severe childhood malaria: relationship of cytokine balance with disease severity. J Infect Dis 2000;182:988–992.

    Google Scholar 

  85. Prada J, Malinowski J, Muller S, Bienzle U, Kremsner PG. Effects of Plasmodium vinckei hemozoin on the production of oxygen radicals and nitrogen oxides in murine macrophages. Am J Trop Med & Hygiene 1996;54:620–624.

    Google Scholar 

  86. Taramelli D, Basilico N, Pagani E, et al. The heme moiety of malaria pigment (beta-hematin) mediates the inhibition of nitric oxide and tumor necrosis factor-alpha production by lipopolysaccharide-stimulated macrophages. Exper Parasitol1995;81:501–511.

    Google Scholar 

  87. Perkins DJ, Kremsner PG, Weinberg JB. Inverse relationship of plasma prostaglandin E-2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria. J Infect Dis 2001;183:113–118.

    Google Scholar 

  88. Clancy R, Varenika B, Huang W, et al. Nitric oxide synthase/ COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol2000;165:1582–1587.

    Google Scholar 

  89. Belmont HM, Levartovsky D, Goel A, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthrit & Rheum 1997;40:1810–1816.

    Google Scholar 

  90. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999;26:318–324.

    Google Scholar 

  91. Knight JC, Kwiatkowski D. Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Proc Assoc Am Physicians 1999;111:290–298.

    Google Scholar 

  92. Abraham LJ, Kroeger KM. Impact of the-308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukocyte Biol 1999;66: 62–566.

    Google Scholar 

  93. Morahan G, Huang DX, Ymer SI, et al. Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat Genetics 2001;27:218–221.

    Google Scholar 

  94. Martin J, Calzada JE, Nieto A. Inducible nitric oxide synthase (NOS2) gene polymorphism and parasitic diseases [letter]. Lancet 1999;353:72.

    Google Scholar 

  95. Xu W, Liu L, Emson PC, Harrington CR, Charles IG. Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. Gene 1997;204:165–170.

    Google Scholar 

  96. Xu W, Humphries S, Tomita M, et al. Survey of the allelic frequency of a NOS2A promoter microsatellite in human populations: assessment of the NOS2A gene and predisposition to infectious disease. Nitric Oxide 2000;4:379–383.

    Google Scholar 

  97. Warpeha KM, Xu W, Liu L, et al. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999;13:1825–1832.

    Google Scholar 

  98. Park CS, Lee HS, Lee HY, Krishna G. An unprocessed pseudogene of inducible nitric oxide synthase gene in human. Nitric Oxide 1997;1:294–300.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, VA and Duke University Medical Centers, Durham, NC

    Marc C. Levesque

  2. Department of Internal Medicine, University of Utah Medical Center, Salt Lake City, UT

    Maurine R. Hobbs & Donald L. Granger

  3. Department of Medicine, Menzies School of Health Research and Northern Territory Clinical School, Darwin, Australia

    Nicholas M. Anstey

  4. Department of Medicine, VA and Duke University Medical Centers, Durham, NC

    Jennifer A. Chancellor, Mary A.M. Misukonis & J. Brice Weinberg

Authors
  1. Marc C. Levesque
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maurine R. Hobbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicholas M. Anstey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jennifer A. Chancellor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mary A.M. Misukonis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Donald L. Granger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Brice Weinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levesque, M.C., Hobbs, M.R., Anstey, N.M. et al. A Review of Polymorphisms in the Human Gene for Inducible Nitric Oxide Synthase (NOS2) in Patients with Malaria. Sepsis 4, 217–231 (2001). https://doi.org/10.1023/A:1012913023602

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012913023602

Search

Navigation